logo
About
R&D
Pipeline
Investors
News
Contact
For Patients
Primary Sclerosing Cholangitis
Nonalcoholic Steatohepatitis (NASH)
(NASH) דלקת כבד על רקע שומני
Investor Relations
Investor Relations
Overview
News & Events
News
Events
Presentations
Contact IR
Email Alerts
Financials & Filings
SEC Filings
Annual Reports
Quarterly Results
Stock
Stock Quote & Chart
Historical Stock Price
Analyst Coverage
Corporate Governance
Board Committees
Board of Directors
Leadership
Documents
News
Events
Presentations
Contact IR
Email Alerts
News
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
Go
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
Go
Email Alerts
Year
All Years
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Keywords
Go
Advanced Search
Search
Search Headlines Only
From
To
Asset Types
Photos
Video
Audio
Documents
Events
Standard
Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update
April 24, 2024
Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis
April 18, 2024
Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024
April 02, 2024
Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis
March 25, 2024
Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate Update
March 07, 2024
Load More
Loading...